Nurix Therapeutics, Inc. NRIX Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months)
Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months) at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s available-for-sale debt securities - unrealized loss position (<12 months).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s available-for-sale debt securities - unrealized loss position (<12 months)?
- Nurix Therapeutics, Inc. (NRIX) reported available-for-sale debt securities - unrealized loss position (<12 months) of $151.57M in Q4 2025.
- How has Nurix Therapeutics, Inc.'s available-for-sale debt securities - unrealized loss position (<12 months) changed year-over-year?
- Nurix Therapeutics, Inc.'s available-for-sale debt securities - unrealized loss position (<12 months) increased by 68.5% year-over-year, from $89.95M to $151.57M.
- What does available-for-sale debt securities - unrealized loss position (<12 months) mean?
- This represents the fair value of available-for-sale debt securities that have been in an unrealized loss position for less than one year. It helps distinguish between temporary market fluctuations and potential long-term impairment. This metric is useful for assessing the short-term volatility impact on the company's balance sheet.